INSIGHTEC, INC.

Lobbying client · Florida · filed 2025 to 2026

Medical device company

$460,000 Reported spend

7 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page is grouped by the client's LDA id (54709), not by name.

Firms hired 1

BALLARD PARTNERS $460,000 7 filings

Reported by year 2 years

2026 $180,000 2 filings
2025 $280,000 5 filings

Issues lobbied 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 3

Veterans Affairs, Dept of (VA) 6
HOUSE OF REPRESENTATIVES 3
SENATE 3

Recent filings 7 total

Q2

BALLARD PARTNERS

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $90,000 income · posted Jul 15, 2026

View → Q1

BALLARD PARTNERS

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $90,000 income · posted Apr 15, 2026

View → Q4

BALLARD PARTNERS

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $90,000 income · posted Jan 14, 2026

View → Q3

BALLARD PARTNERS

3rd Quarter (July 1 - Sep 30) 2025 · $90,000 income · posted Oct 15, 2025

View → Q2

BALLARD PARTNERS

2nd Quarter (Apr 1 - June 30) 2025 · $90,000 income · posted Jul 15, 2025

View → Q1

BALLARD PARTNERS

1st Quarter (Jan 1 - Mar 31) 2025 · $10,000 income · posted Apr 15, 2025

View → RA

BALLARD PARTNERS

1st Quarter (Jan 1 - Mar 31) 2025 · posted Apr 8, 2025

View →

Foreign entities disclosed 1

INSIGHTEC LTD Israel named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.